Novo Nordisk Targets New Gut Hormone to Treat Obesity
This article is for subscribers only.
Novo Nordisk A/S, the world’s biggest maker of insulin for diabetics, has sought patent protection for a synthetic version of an intestinal hormone as part of an effort to develop medicines for treating obesity.
Novo Nordisk filed a patent application for analogues of the hormone PYY with the World Intellectual Property Organization, which published the application last month, the U.S. Federal News Service reported on March 30. Companies can seek protection by filing applications with Geneva-based WIPO, which administers a global patent filing system. Individual countries still must grant patents.